US · VCYT
Veracyte, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- South San Francisco, CA 94080
- Website
- veracyte.com
Price · as of 2025-12-31
$33.09
Market cap 2.89B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $51.32 | +55.09% |
| Intrinsic Value(DCF) | $32.10 | -2.99% |
| Graham-Dodd Method(GD) | $11.12 | -66.38% |
| Graham Formula(GF) | $19.79 | -40.2% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | $0.00 | $0.00 | |||
| 2013 | $17.63 | $93.73 | $50,659.22 | $0.00 | $0.00 |
| 2014 | $7.68 | $32.29 | $18,294.74 | $0.00 | $0.00 |
| 2015 | $5.89 | $27.26 | $537.31 | $0.00 | $0.00 |
| 2016 | $9.41 | $29.45 | $102.61 | $0.00 | $0.00 |
| 2017 | $6.45 | $27.91 | $2.25 | $0.00 | $0.00 |
| 2018 | $20.00 | $40.63 | $39.10 | $0.00 | $0.00 |
| 2019 | $23.91 | $48.69 | $68.95 | $3.77 | $0.00 |
| 2020 | $52.48 | $44.25 | $8.12 | $4.58 | $0.00 |
| 2021 | $23.79 | $44.84 | $6.24 | $0.16 | $0.00 |
| 2022 | $21.09 | $41.98 | $0.42 | $2.75 | $0.00 |
| 2023 | $22.72 | $39.32 | $6.74 | $0.00 | $0.00 |
| 2024 | $32.02 | $47.57 | $35.31 | $7.20 | $9.63 |
| 2025 | $36.01 | $51.32 | $47.25 | $11.12 | $19.79 |
AI valuation
Our deep-learning model estimates Veracyte, Inc.'s (VCYT) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $51.32
- Current price
- $33.09
- AI upside
- +55.09%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$32.10
-2.99% upside
Graham-Dodd
$11.12
-66.38% upside
Graham Formula
$19.79
-40.2% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| VCYT | Veracyte, Inc. | $33.09 | 2.89B | +55% | -3% | -66% | -40% | 42.65 | 2.16 | 5.47 | 27.41 | 25.92 | 6.24 | 69.62% | 14.34% | 12.83% | 5.34% | 7.70% | 4.90% | 0.03 | — | 8.15 | 7.63 | -3.60 | 16452.00% | 1601.00% | 9845.00% | 4.47% | 2.27 | 13.52% | 0.00% | 0.00% | 4.76% | 33.13 | 19.40 | 4.75 | 18.51 |
| ADPT | Adaptive Biotechnologies … | $16.02 | 2.46B | +132% | +239% | — | — | -41.11 | 11.18 | 8.83 | -83.74 | — | 24.93 | 74.24% | -20.62% | -21.48% | -28.23% | -33.39% | -11.31% | 1.28 | -4.85 | 3.34 | 3.08 | -7.04 | -6389.00% | 5477.00% | -5050.00% | -2.00% | -0.51 | -28.61% | 0.00% | 0.00% | 0.00% | -43.75 | -51.06 | 9.02 | 2.04 |
| APLS | Apellis Pharmaceuticals, … | $20.96 | 2.68B | +129% | +661% | -82% | -70% | 116.52 | 7.05 | 2.60 | 37.53 | — | 7.05 | 89.81% | 5.52% | 2.23% | 7.48% | 15.34% | 2.28% | 1.31 | 1.25 | 3.14 | 2.58 | 0.26 | -11125.00% | 2846.00% | -15100.00% | 1.73% | 0.14 | 13.42% | 0.00% | 0.00% | 1.53% | 47.40 | 58.37 | 2.62 | 0.17 |
| FOLD | Amicus Therapeutics, Inc. | $14.37 | 4.51B | +149% | -39% | — | — | -163.34 | 16.15 | 6.98 | 85.82 | — | 70.82 | 87.32% | 5.44% | -4.27% | -11.58% | 3.24% | -3.13% | 1.76 | 0.75 | 2.84 | 1.72 | 5.00 | -5117.00% | 2005.00% | -17972.00% | 0.67% | 0.14 | 7.01% | 0.00% | 0.00% | 0.00% | 133.89 | 154.71 | 7.28 | 1.20 |
| IDYA | IDEAYA Biosciences, Inc. | $32.20 | 2.83B | +1,323% | +773% | -84% | — | -25.71 | 2.86 | 13.37 | -14.94 | — | 2.86 | 97.90% | -72.84% | -51.99% | -10.92% | -39.17% | -10.18% | 0.03 | — | 11.34 | 10.87 | 0.55 | -6190.00% | 302443.00% | -7078.00% | -2.51% | -1.21 | -18.06% | 0.00% | 0.00% | 0.67% | -14.51 | -31.47 | 10.57 | 19.76 |
| IRON | Disc Medicine, Inc. | $66.62 | 2.51B | — | — | — | — | -11.07 | 3.17 | — | -7.50 | -21.38 | 3.17 | 0.00% | — | — | -35.86% | 717.87% | -32.55% | 0.00 | -65.43 | 21.94 | 21.59 | 0.43 | 5177.00% | — | 9202.00% | -7.72% | -4.92 | 551.51% | 0.00% | 0.00% | 0.00% | -6.61 | -8.60 | — | 20.31 |
| KNSA | Kiniksa Pharmaceuticals, … | $44.49 | 3.3B | +56% | +8,673% | -74% | +17% | -79.02 | 6.01 | 5.04 | 33.27 | — | 6.18 | 54.63% | 11.40% | 8.71% | -8.59% | 27.89% | -6.43% | 0.02 | — | 3.79 | 3.09 | -1.73 | -22500.00% | 6009.00% | 0.00% | 0.74% | 0.18 | 13.82% | 0.00% | 0.00% | 0.23% | 38.96 | 118.40 | 4.44 | 11.43 |
| LEGN | Legend Biotech Corporatio… | $19.00 | 1.75B | +139% | +396,718% | -91% | — | -20.39 | 3.10 | 5.14 | -21.66 | — | 3.72 | 62.60% | -48.35% | -28.22% | -13.80% | -112.36% | -8.99% | 0.34 | -14.03 | 4.62 | 4.49 | -0.56 | -6701.00% | 11997.00% | -6199.00% | -4.91% | -0.52 | -58.59% | 0.00% | 0.00% | 0.00% | -8.08 | -15.50 | 3.91 | 2.18 |
| SRRK | Scholar Rock Holding Corp… | $44.27 | 4.52B | — | — | — | — | -14.59 | 9.75 | — | -13.57 | -60.50 | 9.81 | 0.00% | — | — | -82.95% | -14081.23% | -62.67% | 0.18 | -36.87 | 9.61 | 9.36 | 0.47 | 2412.00% | — | 3837.00% | -5.59% | -4.28 | -11231.68% | 0.00% | 0.00% | 2.02% | -12.78 | -16.03 | — | 16.84 |
| TARS | Tarsus Pharmaceuticals, I… | $75.52 | 3.21B | +33% | +191,318% | -100% | — | -48.71 | 9.42 | 7.17 | -54.31 | — | 9.63 | 93.20% | -15.72% | -14.72% | -23.39% | -558.70% | -14.14% | 0.27 | -7.94 | 3.85 | 3.72 | 1.68 | -4821.00% | 14671.00% | -7363.00% | -0.69% | -0.09 | -175.63% | 0.00% | 0.00% | 2.09% | -41.03 | -130.51 | 6.45 | 9.02 |
| ZLAB | Zai Lab Limited | $19.22 | 2.13B | +50% | -49% | — | — | -11.49 | 2.82 | 4.38 | -9.81 | — | 3.16 | 58.60% | -49.86% | -38.15% | -22.56% | -97.09% | -14.89% | 0.31 | -44.05 | 2.45 | 1.91 | 2.88 | -3846.00% | 1533.00% | -4251.00% | -7.88% | -0.36 | -68.36% | 0.00% | 0.00% | 7.89% | -6.77 | -9.77 | 3.37 | -0.13 |
About Veracyte, Inc.
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
- CEO
- Marc A. Stapley
- Employees
- 824
- Beta
- 1.91
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($32.10 ÷ $33.09) − 1 = -2.99% (DCF, example).